Moreover, modified CAR-T cell therapy by depleting the TGF-β signal in CAR-T cells also demonstrates potent efficacy in treating cancers, indicating a promising field by generating more robust and less toxic CAR-T cells by modifying the TGF-β signal pathway. This evidence concerns the gene TGFB1 and cancer.